Scientists from the UCL Great Ormond Street Institute for Child Health and the UCL Cancer Institute have developed new immunotherapy that has shown promising results against neuroblastoma in children . The immunotherapy named CAR T-cell therapy has been derived from modified immune cells (T-Cells) of the patients suffering from neuroblastoma. The T-cells are engineered to contain chimeric antigen receptor (CAR) genes that selectively recognize and inhibit the GD2 surface proteins present on the neuroblastoma tumor cells.
The findings were published in Science Translation Medicine and have revealed the rapid regression of metastatic cells for a transient period. The ability to recognize and inhibit specific cells makes the therapy more beneficial as it does not have any adverse effect on healthy cells. Though the action produced by the CAR T-cell therapy is transient as of now,…
